Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer

被引:73
作者
Tewari K.S. [1 ]
Monk B.J. [1 ]
机构
[1] Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA 92868-3298, 101 The City Drive
关键词
Cervical Cancer; Paclitaxel; Gemcitabine; Clin Oncol; Topotecan;
D O I
10.1007/s11912-005-0007-z
中图分类号
学科分类号
摘要
Because only 16% of patients with metastatic cervical cancer are alive 5 years after diagnosis, the Gynecologic Oncology Group (GOG) has carefully designed and conducted many phase II studies to identify promising drugs. Cisplatin has emerged as the most active single agent with overall response rates of 19%. Recent phase III trials have documented response rates of 27% and 39% when cisplatin has been combined with either paclitaxel or topotecan, respectively. The comparison of cisplatin to cisplatin plus topotecan in GOG-179 has yielded the first study to show a statistically significant impact on the overall response rate, median progression-free survival, and median survival, with all outcome measures favoring the two-drug regimen. Despite these encouraging results, however, most of the responses are partial and of short duration. The need for novel combinations and the implementation of active biologic agents is implicit. The accumulated data in this disease setting, as evidenced by the experience of the GOG, are presented in this review. Copyright © 2005 by Current Science Inc.
引用
收藏
页码:419 / 434
页数:15
相关论文
共 90 条
[81]  
Raymond E., Faivre S., Armand J.P., Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy, Drugs, 60, SUPPL. 1, pp. 15-23, (2000)
[82]  
Kim J.W., Kim Y.T., Kim D.S., Et al., Expression of epidermal growth factor receptor in carcinoma of the cervix, Gynecol. Oncol., 60, pp. 283-287, (1996)
[83]  
Akerman G.S., Tolleson W.H., Brown K.L., Et al., Human papillomavirus typ 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life spaqn of normal human keratinocytes, Cancer Res., 61, pp. 3837-3843, (2001)
[84]  
Fan Z., Shang B.Y., Lu Y., Et al., Reciprocal changes in p27 (Kip 1) and p21 (Cip 1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors, Clin. Cancer Res., 3, pp. 1943-1948, (1997)
[85]  
Shepherd F.A., Pereira J., Ciuleanu T.E., Et al., A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy, J. Clin. Oncol., 22, (2004)
[86]  
Ng M., Cunningham D., Cetuximab (Erbitux): An emerging targeted therapy for epidermal growth factor receptor-expressing tumours, Int. J. Clin. Pract., 58, pp. 970-976, (2004)
[87]  
Tewari K.S., DiSaia P.J., Primary prevention of uterine cervix cancer: Focus on vaccine history and current strategy, Obstet. Gynecol. Clin. North Am., 29, pp. 843-868, (2002)
[88]  
Im S.S., Monk B.J., New developments in the treatment of invasive cervical cancer, Obstet. Gynecol. Clin. North Am., 29, pp. 659-672, (2002)
[89]  
Lim H.Y., Ahn M., Chung H.C., Et al., Tumor-specific gene therapy for uterine cervical cancer using MN/CA9-directed replication-competent adenovirus, Cancer Gene Ther., 11, pp. 532-538, (2004)
[90]  
Boabang P., Kurbacher C.M., Kohlhagen H., Et al., Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor chemosensitivity assay, Anticancer Drugs, 11, pp. 843-848, (2000)